Austedo and Ingrezza: What's the Difference?
Austedo (deutetrabenazine) and Ingrezza (valbenazine) are both medications used to treat tardive dyskinesia, a condition characterized by involuntary, repetitive movements. While they address the same neurological disorder, they are distinct drugs with different chemical compositions and, in some cases, nuances in their use.
How Do These Drugs Work?
Both Austedo and Ingrezza target the neurotransmitter dopamine. Tardive dyskinesia is often associated with the overactivity of dopamine in certain areas of the brain. These medications work by reducing the amount of dopamine that can bind to its receptors.
* Austedo works by inhibiting vesicular monoamine transporter 2 (VMAT2), which is responsible for packaging monoamines, including dopamine, into vesicles for release. By inhibiting VMAT2, Austedo decreases the amount of dopamine available for release into the synapse [1].
* Ingrezza also inhibits VMAT2, thereby reducing dopamine levels in the brain and alleviating the involuntary movements associated with tardive dyskinesia [2].
When Do Austedo and Ingrezza Patents Expire?
Patent expiry dates are crucial for understanding when generic versions of these drugs might become available, potentially impacting pricing and accessibility.
* The principal patent for Austedo, U.S. Patent No. 9,238,721, was originally set to expire in 2033 [3].
* Information regarding specific patent expiry dates for Ingrezza can be found through resources that track drug patents, such as DrugPatentWatch.com [4].
Who Makes Austedo and Ingrezza?
Pharmaceutical companies are responsible for the development and marketing of these medications.
* Austedo is manufactured by Teva Pharmaceuticals [1].
* Ingrezza is developed by Neurocrine Biosciences [2].
What Are the Side Effects Patients Ask About?
While both medications are effective, patients and healthcare providers often discuss potential side effects.
* Common side effects for Austedo can include somnolence, dry mouth, and constipation [1]. A more serious, though less common, side effect is the risk of depression and suicidal ideation or behavior, particularly in individuals with Huntington's disease [1].
* Ingrezza's side effects may include somnolence and potential QT interval prolongation, which is a heart rhythm issue that requires monitoring [2].
How Do Austedo and Ingrezza Compare?
Direct comparisons often focus on efficacy, safety profiles, and administration.
Clinical trials have demonstrated the efficacy of both drugs in reducing the severity of tardive dyskinesia. Differences in patient response, tolerability, and specific dosing regimens may lead physicians to choose one over the other for individual patients. The choice may also depend on other medical conditions a patient has and their potential for drug interactions [1][2].
What Are the Risks of Taking These Medications?
Beyond common side effects, there are specific risks associated with VMAT2 inhibitors.
* Austedo carries a boxed warning regarding the risk of depression and suicidal ideation or behavior in patients with Huntington's disease [1].
* Ingrezza also requires monitoring for potential cardiac issues due to QT interval prolongation [2].
Can Other Treatments Be Used for Tardive Dyskinesia?
While Austedo and Ingrezza are the primary VMAT2 inhibitors approved for tardive dyskinesia, other management strategies exist. These can include dose adjustments of the offending medication (if applicable) or the use of other agents, though VMAT2 inhibitors are currently the most targeted pharmacological treatments for the condition itself.
---
Sources:
1. Teva Pharmaceuticals. Austedo Prescribing Information.
2. Neurocrine Biosciences. Ingrezza Prescribing Information.
3. DrugPatentWatch.com. (n.d.). Deutetrabenazine patents. Retrieved from https://drugpatentwatch.com/
4. DrugPatentWatch.com. (n.d.). Valbenazine patents. Retrieved from https://drugpatentwatch.com/